Literature DB >> 19593513

Trastuzumab.

Edith A Perez1, Frances M Palmieri, Shelly M Brock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593513     DOI: 10.1007/978-0-387-75115-3_12

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN: 0927-3042


× No keyword cloud information.
  3 in total

1.  C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Authors:  Edith A Perez; Robert B Jenkins; Amylou C Dueck; Anne E Wiktor; Patrick P Bedroske; S Keith Anderson; Rhett P Ketterling; William R Sukov; Kazunori Kanehira; Beiyun Chen; Xochiquetzal J Geiger; Cathy A Andorfer; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie R Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

2.  Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.

Authors:  Amylou C Dueck; Monica M Reinholz; Xochiquetzal J Geiger; Kathleen Tenner; Karla Ballman; Robert B Jenkins; Darren Riehle; Beiyun Chen; Ann E McCullough; Nancy E Davidson; Silvana Martino; George W Sledge; Peter A Kaufman; Leila A Kutteh; Julie Gralow; Lyndsay N Harris; James N Ingle; Wilma L Lingle; Edith A Perez
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

3.  Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.

Authors:  Tameka A Bailey; Haitao Luan; Robert J Clubb; Mayumi Naramura; Vimla Band; Srikumar M Raja; Hamid Band
Journal:  J Carcinog       Date:  2011-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.